Real world treatment patterns and unmet needs of migraine preventive treatments in Japan: JMDC claims analysis
Substantial unmet needs exist in migraine preventive treatment in Japan, as demonstrated by low 12-month persistence across all medication classes. Despite higher initial persistence, CGRP mAbs showed similar declining patterns over time, indicating most migraine patients do not remain on their index treatment and suggesting the need for additional options.
Authors
- Chihiro Nishimura
- Gina Ahmadyar (ORCID: https://orcid.org/0000-0002-9235-2876)
- Toru Yamazaki (ORCID: https://orcid.org/0000-0002-5124-756X)
- Takao Takeshima (ORCID: https://orcid.org/0000-0003-2678-6956)
- S. Inoue (ORCID: https://orcid.org/0000-0002-6263-7627)
- Molly Duan
Institutions
- AbbVie (United States) (US)
- Tominaga hospital (JP)
- ABB (Japan) (JP)
- AbbVie (Japan)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1080/03007995.2025.2552277
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- AbbVie Canada